🔍 Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI in Medicine — Cancer & Rare Disease — 2026-09-23 (Wed) Evening News

Daily ReportEvening edition, 18:10 JST

Source links point to the original outlet. The AI Integrated Analysis is auto-generated from the headlines below only and is not intended to add facts beyond them. Not investment advice.

Editions of the day: Morning News (Morning 06:10)Evening News (Evening 18:10)
🌆 Evening Report12:34 JST
Source: Google News RSS / regulators, patient groups and research consortia / ClinicalTrials.gov / YouTube  ·  過去 1 週間以内  ·  31 articles
AI 統合分析 / AI INTEGRATED ANALYSIS2026-09-23 (Wed) — 🌆 Evening Report · 12:34 JST
In the diagnostic field, there are mainly presentations on AI pathology and genome mapping, and there are no headlines indicating specific progress in therapeutic drugs or systems.

Latest news on AI and rare and incurable diseases

Overview

In the diagnostic field, there are mainly presentations on AI pathology and genome mapping, and there are no headlines indicating specific progress in therapeutic drugs or systems. Several companies announced the construction of genetic analysis infrastructure (dataset preparation). There are no headings showing individual trends in the 348 designated intractable diseases.

Diagnosis of rare diseases

MGI announced its AI-enabled pathology portfolio “VisiOmics” in Europe at ECP 2026

News-Medical

. Numerical values showing diagnostic accuracy and shortened time to diagnosis are not listed in the headline and are unknown. Google DeepMind maps 9 billion DNA mutations and shows its potential for use in elucidating rare diseases

WION

. This is the construction of a mutation map, and does not indicate clinical application to cases or improvement in diagnostic rate.

Gene analysis/genome

Precure selects Helix to provide multi-omics testing and AI tools [Genetic Engineering and Biotechnology News]. Pure Genetic Medical and Breakthrough Genomics launch AI-powered “Virtual Geneticist”

Select Science

, There are no specific numerical values such as mutation determination accuracy in the heading. Tempus AI is also building a large-scale whole-genome multimodal dataset

Bitget

Yahoo Finance

. All of these are at the stage of developing research infrastructure and datasets, and are not reports that demonstrate clinical ability to interpret mutations. The Mainichi Keizai article reports that DeepMind used AI to pre-analyze and map the approximately 9 billion single-letter changes (single nucleotide mutations) in human DNA, and appears to be referring to the same initiative as WION's report.

Development of therapeutic drugs

No applicable information.

Nerve/muscular diseases

No applicable information.

Immunology/Collagen disease

No applicable information.

Rare metabolic/endocrine diseases

No applicable information.

System/Patient Support

No applicable information.

Japanese movements

It was reported that Anthropic will establish a biology research institute and begin full-scale AI drug discovery efforts.

Infoseek News

. The target disease/stage (pre-clinical or not, etc.) is not stated in the heading and is unknown. Mainichi Keizai (Korean media) has reported on DeepMind's mapping of DNA mutations, but it does not indicate the movements of systems and institutions in Japan.

Remarks from VIPs

No applicable information.

← 2026-09-23-morningIndex
← AI in Medicine — Cancer & Rare Disease Index